Observational studyBMJ paediatrics open2026
Dosing practices of caffeine therapy for apnoea of prematurity: a retrospective single-centre observational study.
Observational study in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Brain activity as a candidate biomarker for personalised caffeine treatment in premature neonates.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo evaluate caffeine prescribing practices in a tertiary neonatal unit, focusing on initiation, dose adjustment, discontinuation and recommencement, and to assess associations with gestational age and respiratory support.
designRetrospective observational study.
settingNeonatal unit, John Radcliffe Hospital, Oxford, United Kingdom. PATIENTS: Preterm infants born ≤32 weeks gestation and admitted between 1 February 2022 and 31 October 2023. Data extracted from paper patient records included daily caffeine dosing, initiation, discontinuation, recommencement, coadministration with doxapram, demographics and duration of respiratory support. Associations between caffeine administration and clinical factors such as gestational age were assessed using regression.
results168 admissions were analysed from 163 infants. Caffeine was typically initiated with a loading dose of 20 mg/kg, and maintenance doses ranged from 5 mg/kg/day to 25 mg/kg/day. There were 1-8 dose adjustments per admission. Doxapram was administered to 19 infants. Caffeine was discontinued at a median (IQR) postmenstrual age of 34.0 (33.9-34.7) weeks and was recommenced in four infants. Gestational age at birth was negatively correlated with postmenstrual age at discontinuation (r(CI) -0.33 (-0.51 to -0.12), p=0.0029; R²=0.11) and infants born at lower gestational ages received higher doses.
conclusionCaffeine therapy in this unit showed marked variability in dosing, discontinuation and recommencement, highlighting the individualised nature of bedside decision-making, which may reflect clinical response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.